News articles about Seres Therapeutics (NASDAQ:MCRB) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Seres Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.2672110972499 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Seres Therapeutics (MCRB) opened at $10.20 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.53 and a current ratio of 6.53. Seres Therapeutics has a 1-year low of $8.85 and a 1-year high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.22. The company had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $17.29 million. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. Seres Therapeutics’s revenue for the quarter was up 76.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.46) EPS. equities research analysts predict that Seres Therapeutics will post -2.24 earnings per share for the current year.

A number of analysts have recently issued reports on the company. Zacks Investment Research downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cowen reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Monday, October 2nd. CIBC assumed coverage on Seres Therapeutics in a research report on Friday, October 13th. They set an “outperform” rating and a $19.00 price target for the company. Oppenheimer started coverage on Seres Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $19.00 price target for the company. Finally, Citigroup started coverage on Seres Therapeutics in a report on Thursday, October 12th. They set a “positive” rating and a $19.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $18.00.

ILLEGAL ACTIVITY WARNING: “Seres Therapeutics (MCRB) Given Daily News Impact Score of 0.11” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/seres-therapeutics-mcrb-given-daily-news-impact-score-of-0-11/1772371.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Insider Buying and Selling by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.